Mirum Pharmaceuticals, Inc.

For the period ended Sep 30, 2025. Filed Nov 4, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 4, 2025

MIRM$94.42+1.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Revenue:
Product sales, net	$133,010	$90,302	$372,380	$236,979
License and other revenue	—	75	—	495
Total revenue	133,010	90,377	372,380	237,474
Operating expenses:
Cost of sales	25,537	20,806	71,976	58,863
Research and development	42,960	31,710	135,071	96,604
Selling, general and administrative	61,910	50,545	182,902	145,391
Total operating expenses	130,407	103,061	389,949	300,858
Income (loss) from operations	2,603	(12,684)	(17,569)	(63,384)
Other income (expense):
Interest income	3,251	3,469	9,307	10,588
Interest expense	(3,606)	(3,586)	(10,791)	(10,732)
Other income (expense), net	395	(1,087)	2,589	982
Net income (loss) before provision for income taxes	2,643	(13,888)	(16,464)	(62,546)
(Benefit from) provision for income taxes	(262)	347	1,169	1,606
Net income (loss)	$2,905	$(14,235)	$(17,633)	$(64,152)
Net income (loss) per share, basic	$0.06	$(0.30)	$(0.35)	$(1.36)
Net income (loss) per share, diluted	$0.05	$(0.30)	$(0.35)	$(1.36)
Weighted-average shares of common stock outstanding, basic	50,639,231	47,782,619	49,758,104	47,316,789
Weighted-average shares of common stock outstanding, diluted	56,993,841	47,782,619	49,758,104	47,316,789

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.